XML 45 R33.htm IDEA: XBRL DOCUMENT
v3.23.1

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2022
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES |
Schedule of estimated useful lives of property, plant and equipment | The Company's property, plant, and equipment primarily consist of buildings, land, assembly equipment, molding machines, molds, office equipment, furniture, and fixtures. Depreciation and amortization are calculated using the straight-line method over the following useful lives: ​
​ | ​ | ​
Production equipment |  | 3 to 13 years
Office furniture and equipment |  | 3 to 10 years
Buildings |  | 39 years
Building improvements |  | 15 years
​
Schedule of significant customers | The following table reflects our significant customers in 2022, 2021, and 2020: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | Years Ended December 31, |
​ |  | ​ | 2022 |  | 2021 |  | 2020 |
Number of significant customers |  |  | ​ | 4 |  | ​ | 1 |  | ​ | 2 | ​
Aggregate dollar amount of net sales to significant customers | ​ | ​ | $ | 66.4 million | ​ | $ | 113.7 million | ​ | $ | 41.6 million | ​
Percentage of net sales to significant customers | ​ | ​ | ​ | 70.0 | % | ​ | 60.3 | % | ​ | 50.6 | %
​
Schedule of disaggregated information of revenue recognized from contracts with customers and licensing fees recognized | Disaggregated information of revenue recognized from contracts with customers and licensing fees recognized are as follows: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | For the year ended December 31, 2022:
​ |  | ​ | ​ |  | Blood |  | ​ | ​ |  | ​ | ​ |  | Total
​ | ​ | ​ | ​ | ​ | Collection | ​ | EasyPoint® | ​ | Other | ​ | Product
Geographic Segment | ​ | Syringes | ​ | Products | ​ | Needles | ​ | Products | ​ | Sales
U.S. sales (excluding U.S. government) | ​ | $ | 29,283,122 | ​ | $ | 2,685,785 | ​ | $ | 4,481,202 | ​ | $ | 42,166 | ​ | $ | 36,492,275
Sales to U.S. government | ​ | ​ | 15,731,136 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 15,731,136
North and South America sales (excluding U.S.) | ​ |  | 28,720,378 | ​ |  | — | ​ |  | 2,608 | ​ |  | 403,834 | ​ |  | 29,126,820
Other international sales | ​ |  | 13,004,225 | ​ |  | 268,064 | ​ |  | 190,468 | ​ |  | 5,950 | ​ |  | 13,468,707
Total | ​ | $ | 86,738,861 | ​ | $ | 2,953,849 | ​ | $ | 4,674,278 | ​ | $ | 451,950 | ​ | $ | 94,818,938
​ ​ ​ ​ ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | For the year ended December 31, 2021:
​ |  | ​ | ​ |  | Blood |  | ​ | ​ |  | ​ | ​ |  | Total
​ | ​ | ​ | ​ | ​ | Collection | ​ | EasyPoint® | ​ | Other | ​ | Product
Geographic Segment | ​ | Syringes | ​ | Products | ​ | Needles | ​ | Products | ​ | Sales
U.S. sales (excluding U.S. government) | ​ | $ | 42,770,403 | ​ | $ | 2,171,680 | ​ | $ | 8,892,712 | ​ | $ | 53,341 | ​ | $ | 53,888,136
Sales to U.S. government | ​ | ​ | 113,662,440 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 113,662,440
North and South America sales (excluding U.S.) | ​ |  | 14,345,874 | ​ | ​ | 4,800 | ​ | ​ | 100,848 | ​ | ​ | 109,714 | ​ |  | 14,561,236
Other international sales | ​ |  | 5,551,592 | ​ | ​ | 71,670 | ​ | ​ | 642,880 | ​ | ​ | 4,500 | ​ |  | 6,270,642
Total | ​ | $ | 176,330,309 | ​ | $ | 2,248,150 | ​ | $ | 9,636,440 | ​ | $ | 167,555 | ​ | $ | 188,382,454
​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | For the year ended December 31, 2020:
​ |  | ​ | ​ |  | Blood |  | ​ | ​ |  | ​ | ​ |  | Total
​ | ​ | ​ | ​ | ​ | Collection | ​ | EasyPoint® | ​ | Other | ​ | Product
Geographic Segment | ​ | Syringes | ​ | Products | ​ | Needles | ​ | Products | ​ | Sales
U.S. sales (excluding U.S. government) | ​ | $ | 30,446,858 | ​ | $ | 2,116,108 | ​ | $ | 9,542,122 | ​ | $ | 64,375 | ​ | $ | 42,169,463
Sales to U.S. government | ​ |  | 31,634,343 | ​ |  | — | ​ | ​ | — | ​ | ​ | — | ​ |  | 31,634,343
North and South America sales (excluding U.S.) | ​ | ​ | 5,733,116 | ​ | ​ | 8,450 | ​ | ​ | 86,816 | ​ | ​ | 1,064,768 | ​ | ​ | 6,893,150
Other international sales | ​ |  | 917,478 | ​ |  | 239,329 | ​ |  | 235 | ​ |  | 8,455 | ​ |  | 1,165,497
Total | ​ | $ | 68,731,795 | ​ | $ | 2,363,887 | ​ | $ | 9,629,173 | ​ | $ | 1,137,598 | ​ | $ | 81,862,453
​
Schedule of diluted EPS under the treasury stock method | The calculation of diluted EPS under the treasury stock method included the following shares in 2022, 2021, and 2020: ​
​ | ​ | ​ | ​ | ​ | ​
​ | Years Ended December 31,
​ | 2022 |  | 2021 |  | 2020
Common Stock underlying issued and outstanding stock options | 65,597 | ​ | 141,435 | ​ | 131,347
Common stock issuable upon the conversion of convertible preferred shares | — | ​ | 232,445 | ​ | —
​ | 65,597 | ​ | 373,880 | ​ | 131,347
​
Schedule of earnings per share | In both 2022 and 2020, preferred stock was excluded from the calculation of diluted EPS because the effect was antidilutive. ​ The potential dilution, if any, is shown on the following schedule: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | Years Ended December 31,
​ |  | ​ | 2022 |  | 2021 |  | 2020
Net income | ​ | ​ | $ | 5,078,557 | ​ | $ | 56,064,241 | ​ | $ | 24,223,013
Preferred stock dividend requirements | ​ | ​ |  | (232,444) | ​ |  | (241,703) | ​ |  | (573,868)
Deemed contribution on extinguishment of preferred stock | ​ | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 2,975,708
Income applicable to common shareholders | ​ | ​ | $ | 4,846,113 | ​ | $ | 55,822,538 | ​ | $ | 26,624,853
Average common shares outstanding | ​ | ​ |  | 32,896,348 | ​ |  | 33,870,819 | ​ |  | 33,169,307
Average common and common equivalent shares outstanding — assuming dilution | ​ | ​ |  | 32,961,945 | ​ |  | 34,244,699 | ​ |  | 33,300,654
Basic earnings per share | ​ | ​ | $ | 0.15 | ​ | $ | 1.65 | ​ | $ | 0.80
Diluted earnings per share | ​ | ​ | $ | 0.15 | ​ | $ | 1.63 | ​ | $ | 0.80
​

X
- Definition Tabular disclosure of the useful life of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. + References No definition available. + Details
Name: | rvp_UsefulLifeOfPropertyPlantAndEquipmentTableTextBlock
Namespace Prefix: | rvp_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_AccountingPoliciesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257 + Details
Name: | us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit). + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257 + Details
Name: | us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -URI https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -URI https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -URI https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 16 -URI https://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -URI https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592 Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 21 -URI https://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592 + Details
Name: | us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration